122 related articles for article (PubMed ID: 17725802)
1. Rituximab responsive immune thrombocytopenic purpura in an adult with underlying autoimmune lymphoproliferative syndrome due to a splice-site mutation (IVS7+2 T>C) affecting the Fas gene.
Wei A; Cowie T
Eur J Haematol; 2007 Oct; 79(4):363-6. PubMed ID: 17725802
[TBL] [Abstract][Full Text] [Related]
2. ALPS: an autoimmune human lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis.
Puck JM; Sneller MC
Semin Immunol; 1997 Feb; 9(1):77-84. PubMed ID: 9106310
[TBL] [Abstract][Full Text] [Related]
3. Effect of anti-CD20 (rituximab) on resistant thrombocytopenia in autoimmune lymphoproliferative syndrome.
Heelan BT; Tormey V; Amlot P; Payne E; Mehta A; Webster AD
Br J Haematol; 2002 Sep; 118(4):1078-81. PubMed ID: 12199788
[TBL] [Abstract][Full Text] [Related]
4. Should rituximab be used before or after splenectomy in patients with immune thrombocytopenic purpura?
Cooper N; Evangelista ML; Amadori S; Stasi R
Curr Opin Hematol; 2007 Nov; 14(6):642-6. PubMed ID: 17898569
[TBL] [Abstract][Full Text] [Related]
5. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.
Braendstrup P; Bjerrum OW; Nielsen OJ; Jensen BA; Clausen NT; Hansen PB; Andersen I; Schmidt K; Andersen TM; Peterslund NA; Birgens HS; Plesner T; Pedersen BB; Hasselbalch HC
Am J Hematol; 2005 Apr; 78(4):275-80. PubMed ID: 15795920
[TBL] [Abstract][Full Text] [Related]
6. Autoimmune lymphoproliferative syndrome (ALPS) in a patient with a new germline Fas gene mutation.
Del-Rey MJ; Manzanares J; Bosque A; Aguiló JI; Gómez-Rial J; Roldan E; Serrano A; Anel A; Paz-Artal E; Allende LM
Immunobiology; 2007; 212(2):73-83. PubMed ID: 17336828
[TBL] [Abstract][Full Text] [Related]
7. Successful use of anti-CD20 (rituximab) in severe, life-threatening childhood immune thrombocytopenic purpura.
Bengtson KL; Skinner MA; Ware RE
J Pediatr; 2003 Nov; 143(5):670-3. PubMed ID: 14615744
[TBL] [Abstract][Full Text] [Related]
8. A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia.
Saleh MN; Gutheil J; Moore M; Bunch PW; Butler J; Kunkel L; Grillo-López AJ; LoBuglio AF
Semin Oncol; 2000 Dec; 27(6 Suppl 12):99-103. PubMed ID: 11226008
[TBL] [Abstract][Full Text] [Related]
9. Mycophenolate mofetil as an alternate immunosuppressor for autoimmune lymphoproliferative syndrome.
Kossiva L; Theodoridou M; Mostrou G; Vrachnou E; Le Deist F; Rieux-Laucat F; Kanariou MG
J Pediatr Hematol Oncol; 2006 Dec; 28(12):824-6. PubMed ID: 17164652
[TBL] [Abstract][Full Text] [Related]
10. Refractory autoimmune thrombocytopenic purpura: responses to treatment with a recombinant antibody to lymphocyte membrane antigen CD20 (rituximab).
Narang M; Penner JA; Williams D
Am J Hematol; 2003 Dec; 74(4):263-7. PubMed ID: 14635207
[TBL] [Abstract][Full Text] [Related]
11. Treatment of a patient with chronic immune thrombocytopenic purpura with rituximab and monitoring by flow cytometric analysis.
Thude H; Gruhn B; Werner U; Schorner U; Häfer R; Zintl F; Barz D
Acta Haematol; 2004; 111(4):221-4. PubMed ID: 15153715
[TBL] [Abstract][Full Text] [Related]
12. Successful treatment of a patient with hairy cell leukemia and pentostatin-induced autoimmune thrombocytopenia with rituximab.
Hensel M; Ho AD
Am J Hematol; 2003 May; 73(1):37-40. PubMed ID: 12701118
[TBL] [Abstract][Full Text] [Related]
13. Low rate of long-lasting remissions after successful treatment of immune thrombocytopenic purpura with rituximab.
Schweizer C; Reu FJ; Ho AD; Hensel M
Ann Hematol; 2007 Oct; 86(10):711-7. PubMed ID: 17622529
[TBL] [Abstract][Full Text] [Related]
14. Rituximab is effective for selected patients with chronic steroid-refractory immune thrombocytopenic purpura.
Lalayanni C; Stavroyianni N; Saloum R; Tsompanakou A; Anagnostopoulos A
Hematology; 2004 Aug; 9(4):287-9. PubMed ID: 15621736
[TBL] [Abstract][Full Text] [Related]
15. Successful use of rituximab in Evans syndrome and refractory immune thrombocytopenic purpura.
Kashif M; Qureshi A; Adil SN; Khurshid M
J Pak Med Assoc; 2010 Jan; 60(1):64-5. PubMed ID: 20055286
[TBL] [Abstract][Full Text] [Related]
16. Autoimmune thrombocytopenic purpura complicating lymphoproliferative disorders.
Lim SH; Ifthikharuddin JJ
Leuk Lymphoma; 1994 Sep; 15(1-2):61-4. PubMed ID: 7858503
[TBL] [Abstract][Full Text] [Related]
17. Partial response to anti-CD20 monoclonal antibody treatment of severe immune thrombocytopenic purpura in a patient with common variable immunodeficiency.
Carbone J; Escudero A; Mayayo M; Ballesteros M; Perez-Corral A; Sanchez-Ramon S; Sarmiento E; Micheloud D; Fernandez-Cruz E
Ann N Y Acad Sci; 2005 Jun; 1051():666-71. PubMed ID: 16127007
[TBL] [Abstract][Full Text] [Related]
18. Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): report of three cases.
Koulova L; Alexandrescu D; Dutcher JP; O'Boyle KP; Eapen S; Wiernik PH
Am J Hematol; 2005 Jan; 78(1):49-54. PubMed ID: 15609292
[TBL] [Abstract][Full Text] [Related]
19. HLA B44 is associated with decreased severity of autoimmune lymphoproliferative syndrome in patients with CD95 defects (ALPS type Ia).
Vacek MM; Schäffer AA; Davis J; Fischer RE; Dale JK; Adams S; Straus SE; Puck JM
Clin Immunol; 2006 Jan; 118(1):59-65. PubMed ID: 16257267
[TBL] [Abstract][Full Text] [Related]
20. Response to steroid therapy in autism secondary to autoimmune lymphoproliferative syndrome.
Shenoy S; Arnold S; Chatila T
J Pediatr; 2000 May; 136(5):682-7. PubMed ID: 10802504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
